Interleukin 2 and Psoriasis

Archives of Dermatology

Volumn 124, Issue 12, 1988, Pages 1811-1815

  Lee, Roberta E ^a,b   Gaspari, Anthony A ^a   Lotze, Michael T ^a   Chang, Alfred E ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADULT; CASE REPORT; DRUG THERAPY; ERYTHRODERMA; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY;

ADULT; BIOPSY; CARCINOMA, RENAL CELL; CASE REPORT; HUMAN; INTERLEUKIN-2; KILLER CELLS; MALE; MIDDLE AGE; PSORIASIS;

EID: 0024231841     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1988.01670120027005     Document Type: Article

References (17)

1. Rosenberg SA, Lotze MT, Muul LM, et al: Clinical experience with the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987;316:889–897.
2. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–1492.
3. Lotze MT, Chang AE, Seipp CA, et al: High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. JAMA 1986;256:3117–3124.
4. Gaspari AA, Lotze MT, Rosenberg SA, et al: Dermatolotic changes associated with interleukin-2 administration. JAMA 1987;258:1624–1629.
5. Katayama H, Kawada A: Exacerbation of psoriasis induced by indomethacin. J Dermatol 1981;8:323–327.
6. Kern AB: Indomethacin for psoriasis. Arch Dermatol 1966;93:239–240.
7. Ellis CN, Fallon JD, Kang S, et al: Topical application of nonsteroidal anti-inflammatory drugs prevents vehicle-induced improvement of psoriasis. J Am Acad Dermatol 1986;14:39–43.
8. Papa MZ, Vetto JT, Ettinghausen SE, et al: Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin-2 in mice. Cancer Res 1986;46:5618–5623.
9. Vetto JT, Papa MZ, Lotze MT, et al: Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroid. J Clin Oncol 1987;5:496–503.
10. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986;137:1735–1742.
11. Braverman IM, Yen A: Ultrastructure of the human dermal microcirculation. J Invest Dermatol 1977;68:44–52.
12. Quesada JR, Gutterman JU: Psoriasis and alpha-interferon. Lancet 1986;1:1466–1468.
13. Livden JK, Bjerke JR, Degre M, et al: The effect of Goeckerman therapy on interferon in serum and suction blister fluid from patients with psoriasis. Br J Dermatol 1986;114:217–225.
14. Diezel W, Waschke SR, Sonnichsen N: Detection of interferon in the sera of patients with psoriasis, and its enhancement by PUVA treatment. Br J Dermatol 1983;109:549–552.
15. Lotze MT, Matory Y, Ettinghausen SE, et al: In vivo administration of purified human interleukin-2. J Immunol 1985;135:2865–2875.
16. Ellis CN, Gorsulowsky DC, Hamilton TA, et al: Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110–3116.
17. Bunjes D, Hardt C, Rollinghoff M, et al: Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin-1 and interleukin-2. Eur J Immunol 1981;11:657–661.